PATENT COOPERATION TREATY

REC'D 1 6 JAN 2006

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

PCT

(PCT Article 36 and Rule 70)

	OR FURTHER ACTION See	Form PCT/IPEA/416				
2031778PC/or	rnational filing date (day/month/ye	ear) Priority date (day/month/year)				
Modification of Particular		06-10-2003				
1 PC 1 / F 1 2 0 0 2 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	-10-2004	00 20 000				
International Patent Classification (IPC) or nat	ional classification and IPC	·				
See supplemental Box		i				
Applicant						
OY Juvantia Pharma Ltd	et al					
		the this International Preliminary Examining				
This report is the international prelimi Authority under Article 35 and transn	nary examination report, established to the applicant according to	ed by this International Preliminary Examining Article 36.				
2. This REPORT consists of a total of		his cover sheet.				
		sheets as follows:				
a. (sent to the applicant and	l to the International Bureau) a tot	al of sheets, as follows:				
sheets of the desc	ription, claims and/or drawings wi	hich have been amended and are the basis of this report y this Authority (see Rule 70.16 and Section 607 of the				
A deministrative It	netmictions)					
sheets which sup	ersede earlier sheets, but which thi	is Authority considers contain an amendment that goes on as filed, as indicated in item 4 of Box No. I and the				
beyond the discis	osure in the international approant	on as mos, as more as				
	I Person only) a total of (indicate t	type and number of electronic carrier(s))				
	containing a semien	ce listing and/or tables related thereto, in electronic				
form only, as indicated i	form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the					
Administrative Instruction	ons).					
 This report contains indications relat 	ing to the following items:					
Box No. I Basis of the	ie report					
Box No. II Priority		2. 4				
Box No. III Non-estab	dishment of opinion with regard to	novelty, inventive step and industrial applicability				
Box No. IV Lack of u	nity of invention					
Box No. V Reasoned	statement under Article 35(2) with	h regard to novelty, inventive step or industrial				
	applicability; citations and explanations supporting such statement					
1 20/12/5/		ion				
Box No. VII Certain defects in the international						
Box No. VIII Certain o	bservations on the international ap	pheanon				
D. C. I. Live She demand	Date of o	completion of this report				
Date of submission of the demand		-				
01 10 2005	03-0	1~2006				
21-10-2005		zed officer				
Name and mailing address of the IPEA/SE Patent- och registreringsverket	710010					
Box 5055	2017	eig Gustavsson/EÖ				
S-102 42 STOCKHOLM Facsimile No. +46 8 667 72 88	Telepho	one No. +46 8 782 25 00				

Facsimile No. +46 8 667 72 88
Form PCT/IPEA/409 (cover sheet) (April 2005)

International application No.

PCT/FI2004/000583

Sunn	lement	ol 1	Rav
DUDD	remen	222 1	

In case the space in any of the preceding boxes is not sufficient. Continuation of: Cover sheet

INTERNATIONAL PATENT CLASSIFICATION (IPC):

C07K 5/065 (2006.01) A61K 38/05 (2006.01)

Form PCT/IPEA/409 (Supplemental Box) (April 2005)

International application No.

PCT/FI2004/000583

Box	No. I]	Basis	s of the report	
1.	With r	recard	to the	ne language, this report is based on:	
1.				ational application in the language in which it was filed	Į
	Ħ	a tras	nelatio	ion of the international application into	·
	_	whic	h is th	the language of a translation furnished for the purposes or:	
				nternational search (Rules 12.3(a) and 23.1(b))	
				publication of the international application (Rule 12.4(a))	1
		L_		international preliminary examination (Rules 55.2(a) and/or 55.3(a))	
2.	furnis	shed to ire not	o the i t anne	the elements of the international application, this report is based on (replacement sheets which receiving Office in response to an invitation under Article 14 are referred to in this report as "originated to this report):	have been inally filed"
	\boxtimes	the	interr	national application as originally filed/furnished	i
		the	descr	rription: as originally filed/	furnished
		pag	_	received by this Authority on	
			ges* _	in the Authority on	
			clain		
1		pag		as originally filed/	
			ges*	as amended (together with any statement) under	r Article 19
ŀ		pa	ges*		
1		pa	ges*	received by this Authority on	
		the	e drav	wings: as originally filed	/furnished
		-	ges	and by this Authority on	
		-	ges* ges*		
				ence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.	
3.		т [he am	nendments have resulted in the cancellation of:	
•		1		the description, pages	
1				the claims, Nos.	
				the drawings, sheets/figs	
				the sequence listing (specify):	
				any table(s) related to the sequence listing (specify):	
4	. [_ n	his renade, 0.2(c)	report has been established as if (some of) the amendments annexed to this report and listed below, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplements)).	had not been ntal Box (Rule
				the description, pages	
				the claims, Nos.	
				the drawings, sheets/figs	
				the sequence listing (specify):	
				any table(s) related to the sequence listing (specify):	
	* If	item 4	appli	lies, some or all of those sheets may be marked "superseded."	

International application No.

PCT/FI2004/000583

F	Sox No. V	Reasoned statement und citations and explanatio	ler Article 35	(2) with regard to novelty, inventive step or industrial applicability; g such statement	
-					
'	. Statement		Claims		YES
	Novelty (N)		Claims	1-11	NO
					YES
Inventive step (IS)		Claims Claims	1-11	NO	
			Ciamis		YES
١	Indus	strial applicability (IA)	Claims	1-11	NO
		•	Claims		
	Indus		Claims Claims	1-11	

2. Citations and explanations (Rule 70.7)

Cited documents:

- D1) WO 03026575 A2
- D2) EP 1388537 A1
- D3) Science, Vol.282 (1998), pages 737-740

D1 and D2 show closely related compounds. However, these known compounds, which are excluded from the general formula of claim 1 by a disclaimer, have another use than the claimed compounds.

Thus, the invention defined in claims 1-11 has novelty and inventive step.

shows compounds with amide or peptide bonds, compounds interact with the different subtypes of somatostatin receptors. However these compounds have a different structure than the compounds of the present application.

The invention defined in claims 1- 11 is not disclosed by any of these documents.

The cited prior art does not give any indication that would lead a person skilled in the art to the claimed compounds and their use. Therefore, the claimed invention is not obvious to a person skilled in the art.

International application No.

PCT/FI2004/000583

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

The term "a disease or condition where interaction with the somatostatin receptor subtype 4 optionally together with subtype 1 is indicated" in claim 11, although indisputably having a pharmacological effect, cannot in itself be regarded as a therapeutic application.

There are an undefined number of diseases which might be related to these pharmacological effects. A practical application needs to be found in the form of a defined treatment of a specified pathological condition, this being an essential technical feature, in order to render claim 11 clear according to Article 6 PCT.

Form PCT/IPEA/409 (Box No. VIII) (April 2005)